by Dr.Harald Wiesendanger– Klartext
What the mainstream media is hiding
The number of cases of autism is exploding worldwide. They bring brilliant growth prospects to the pharmaceutical industry. Where is fundamental research into the causes, and where are precautionary measures urgently needed?
It avoids eye contact. It responds little to voices, even when addressed by its name. He doesn’t play with other children – he prefers to do that alone. It rarely points to objects it wants. It uses just a few gestures and sounds to get attention. It does not imitate smiles, waves, or other behaviors of a counterpart. It appears rigid, lethargic, and listless. Because it hardly reacts to its surroundings, it seems downright deaf and blind. His behavior appears stereotypical and unimaginative; he hates change. Above all, it deals extensively with unusual detail. It persistently repeats certain actions, turning them into rituals that it doesn’t want to give up. Interrupted or prevented from their odd routines, they will occasionally respond with fits of screaming, aggressive outbursts, and panic attacks. His language seems limited and one-sided; often, it just repeats statements or questions. It seems walled in a lifeless inner world.
A nightmare for his perplexed parents.
Plus 27,000 percent – an unparalleled catastrophe
In the early 1970s, only one in 10,000 children in the USA were affected by such an “autism spectrum disorder” (ASD), and by the end of the 1980s, it was one in 2,000. Since then, the number of cases has exploded. In the early 1970s, only one in 10,000 children in the United States was considered autistic. By 2016, their proportion rose to an alarming 1:48. In 2020; it was already 3.49%. That means one in thirty children and adolescents ages 3 to 17 have already been diagnosed with ASD — a staggering 53% increase since 2017. In half a century, the proportion of autistic children in America has increased by 27,000 percent. An unparalleled catastrophe.
For too long, health authorities played down the issue: They stubbornly denied that there was an almost exponentially growing problem. Only public awareness of the disease has increased, and children are observed more carefully. Parents, family doctors, and psychologists are more vigilant, and diagnostics have become more precise. In this way, you can recognize the typical symptoms earlier and more frequently.
But a rethink is gradually taking place – with the healthcare industry as the pioneer of a long overdue reassessment. Because it is not an imaginary but an actual increase in those affected that opens up magnificent prospects for profit, with annual growth rates of between 3.4% and 7.4% up to 2030. According to a recently published study by the institute, 360 Research Reports had ASD in 2021, a global “market value” of approximately US$9 billion; in five years, it is expected to reach $11.42 billion. Analysts from Market Research Future are even more confident. The ASD market will grow from the current $23.7 billion to $42.3 billion by 2030. This includes diagnostics, medicines, costs for treatment centers, support measures, and care. Among the top beneficiaries, the report ranks the usual suspects: Pfizer, Eli Lilly, Merck, Novartis, Johnson & Johnson, Bristol-Myers Squibb, and Otsuka.
The overall economic damage is many times greater. In the USA alone, it amounts to several hundred billion dollars annually; US market researcher Toby Rogers estimates it will increase to one trillion within the next decade. (1) In addition to diagnostics and therapy, this includes, among other things, wage losses for those affected and carers – usually mothers -supporting services, higher education costs, and assisted living.
Autism drugs without approval: a veritable gold mine
What medicines? To date, there is not a single approved drug for autism. Zero.
In January 2018, the US Food and Drug Administration (FDA) granted a new development by the multinational pharmaceutical Roche, Balovaptan, the coveted status of a “breakthrough therapy”: one that could be approved more quickly because the first preliminary data from clinical studies indicate that it could have serious consequences diseases are to be treated. Five years later, however, these studies are still ongoing. That suggests more of a non-stop than a blockbuster in Roche’s pipeline.
Nevertheless, the pharmaceutical industry is already earning a lot from ASD. This is made possible by “off-label use”: Doctors are allowed to prescribe a drug beyond the approval limits if practical experience and studies indicate that it is also useful for indications or patient groups other than those originally intended. Pharmaceutical representatives, trade press, and training courses will help you along the way. And so, 30 to 50% of all ASD symptom carriers have long been using: stimulants, anticonvulsants, and anxiety suppressants, but also antidepressants: including tricyclic ones like amitriptyline, selective serotonin reuptake inhibitors (SSRI) like fluoxetine and citalopram. A benefit of autism has not been scientifically proven – so what? It’s the same way off-label.
Without batting an eyelid, one in six autistic children is even prescribed antipsychotics: drugs designed to target schizophrenia, mania, and delusional states—most notably Risperdal and Abilify, two of the most toxic psychiatric drugs out there. They are said to alleviate accompanying symptoms such as aggressiveness, compulsions, and stereotypes; they are intended to improve language development, play, and social behavior. Of course, the severe side effects are not necessarily what an autistic heart desires and needs: strokes, epilepsy, involuntary muscle cramps, heart problems, weight gain, balance and speech disorders, diabetes, addictive behavior, depression, anxiety, akathisia – an indomitable motor restlessness – leaden tiredness and Weakness. So far, the pharmaceutical giant Johnson & Johnson has had to pay $2.2 billion in civil and criminal fines for criminally marketing Risperdal. Courts had found that the group, in conjunction with its subsidiary Janssen, downplayed potentially life-threatening risks, even denied them. J&J paid – and then carried on as usual. (2)
In autism, too, polypharmacy isn’t just the exception—it’s the startling rule. Because affected children and adolescents are often on record with more than one behavioral disorder, up to 87% of them are taking two or more drugs simultaneously. No one can predict which interactions may occur.
Too little research into causes
While more and more money is poured into research into lucrative therapeutics, far too little research into the causes continues to take place. As soon as she threatens to unearth unpopular truths, she is more likely to be hindered; Publications are made more difficult, research funds blocked, and scientists sidelined and defamed.
The autism plague began after an unprecedented vaccination mania gripped pediatric medicine. In the 1970s, the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute recommended just six vaccinations: against measles, mumps, rubella, diphtheria, tetanus, and poliomyelitis (poliomyelitis). In the meantime, 31 are to take place before the child reaches the age of two. As of 2021, US children have received 72 doses of the vaccine, with over 250 more on the way. To this day, vaccines contain aluminum and mercury, either as an effective enhancer, as a preservative, or as an impurity from the manufacturing process. They do brain damage. A study found a constantly increased aluminum content in the brain tissue of autistic people.
The fact that “the incidence of autism in vaccinated and unvaccinated children does not differ,” as Wikipedia would like us to believe, invites conjectures as to whose fee lists its admins are on. In fact, autism is considered to be almost 10 times more common among vaccinated (1.1%) than unvaccinated (0.14%). (3) According to a telephone survey of parents of 17,000 American children, vaccinations increase the risk of autism by 61% among 4- to 17-year-olds and by as much as 112% among adolescents – those aged 11 and over. On Big Pharma’s strings, health authorities cover up these connections and remove unwanted data, as whistleblowers occasionally reveal.
But environmental toxins also contribute to autism. These include lead, arsenic, and copper, even in baby food, as well as phthalates, which are often used as plasticizers in polyvinyl chloride (PVC) and other plastics, such as flooring, children’s toys, and rubber products. (4)
High air pollution (5) also increases the risk of autism – proven, for example, for prenatal exposure to ozone. (6)
Drugs are also suspected. Multiple studies have shown that when expectant mothers take paracetamol, their offspring’s risk of autism increases by up to 214% (7) – and even more when they give it to babies and young children. (8) Pregnant women who take antidepressants double the risk of their unborn child having autism, the University of Montreal found when it analyzed data from more than 145,000 women. (9) Even drug residues in drinking water have come under reasonable suspicion of promoting autism.
Numerous studies indicate that pesticides also play a significant role. For example, researchers at the University of Los Angeles studied nearly 3,000 ASD patients who were born between 1998 and 2010 in California’s Central Valley, an agricultural valley 600 km long north of San Francisco; for comparison, they included 35,000 subjects who had grown up there without a diagnosis of autism. Using California’s Pesticide Use Registry, the researchers analyzed which study participants were exposed to at least one of 11 common pesticides before birth and during childhood. This group showed a 10% increased likelihood of autism. The prime suspect is the ubiquitous glyphosate, the active ingredient in Monsanto’s Roundup herbicide.
Autism affects boys four times more often than girls. This “gender gap” indicates that genetic factors play a part in determining how much damage toxins cause. So, is ASD “largely genetic”? This is how trivializers who want to distract argue. One could just as well attribute the lung cancer of heavy smokers mainly to an unfavorable genetic makeup. If every nicotine junkie were equipped with an immune system that was just as fabulous as the legendary chain smoker Helmut Schmidt once was: Wouldn’t smoker’s cancer then be extremely rare?
The only way out: consistent precaution
Green eyes, bright orange hair, a pink dress, with a toy rabbit named Fluffster: On April 10, 2017, an autistic muppet named Julia entered the “Sesame Street” stage for the first time. Its creators are committed to using Julia to “increase understanding” and “de-stigmatize” ASD as part of a nationwide “See Amazing in All Children” initiative. (10)
This approach, which deserves praise for empathy and tolerance, is trending. Instead of firmly countering the ASD phenomenon, it is housed under the umbrella of “neurodiversity” (11) – and thus ultimately downplayed as an expression of “diversity” that primarily requires “acceptance.” Emphasizing the often astounding insular talents of autistic people, praising them for them, and letting them be proud, must not, however, mislead us into downplaying the burdens on those affected and the often immense challenges for relatives. Autism is a fate that every child should be spared, as should their family. It is no coincidence that people suffer from loneliness, depression, and anxiety disorders much more often than the average general population, is under greater social pressure, and are often excluded and bullied. Happiness in life? Every third autistic person thinks of suicide; according to some studies, even two-thirds do it, and nine times more likely to kill themselves. On average, autistic people die 16 years earlier. (12)
Anyone who seriously wants to curb the autism epidemic must therefore do everything possible to keep children away from any potential pathogens – from birth, even in the womb. “The tragedy is that we know very well how to prevent most cases of autism — by not exposing children’s bodies to toxins,” said Toby Rogers. “But most politicians and the mainstream media are refusing to have this conversation so as not to anger the toxic industries – especially the pharmaceutical industry – that run this country. (…) It is imperative that we find a way to keep toxins out of children’s bodies, both through legislation and by boycotting products that cause harm. That’s the only way forward.” (13)
(Harald Wiesendanger)
Remarks
1 Zit. nach The Defender, 14.3.2023, https://childrenshealthdefense.org/defender/herzzerreissend-pharma-sieht-exponentielles-wachstum-im-milliardenschweren-markt-fuer-autismus-medikamente/?lang=de
2 Peter C. Gøtzsche: Tödliche Medizin und organisierte Kriminalität: Wie die Pharmaindustrie unser Gesundheitswesen korrumpiert. München 2014, S. 66 f.
3 Jon Baio: “Prevalence of Autism Spectrum Disorders – Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008”, MMWR Surveill Summ. 30.3.2012, S. 1-19, https://pubmed.ncbi.nlm.nih.gov/22456193/
4 Neurotoxikologie 30 (5) September 2009, S. 822–831, https://translate.google.com/website?sl=en&tl=de&hl=en&u=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom%3Dpubmed%26retmode%3Dref%26cmd%3Dprlinks%26id%3D19822263
5 https://www-naturalnews-com.translate.goog/2019-05-06-studies-determine-link-between-air-pollution-autism-risk.html?_x_tr_sl=en&_x_tr_tl=de&_x_tr_hl=en ; https://www-naturalnews-com.translate.goog/019470_Autism_air_pollution.html?_x_tr_sl=en&_x_tr_tl=de&_x_tr_hl=en
6 Umweltgesundheitsperspektive 121 (3) März 2013, S. 380-386. doi: 10.1289/ehp.1205827. Epub 18. Dezember 2012, https://pubmed-ncbi-nlm-nih-gov.translate.goog/23249813/
7 JAMA Psychiatry 30. Oktober 2019 DOI: 10.1001/jamapsychiatry.2019.3259, https://pubmed.ncbi.nlm.nih.gov/31664451/
8 Int. Med. Auflösung 45 (2) April 2017, S. 407-438, https://pubmed-ncbi-nlm-nih-gov.translate.goog/28415925/
9 https://www.deutsche-apotheker-zeitung.de/daz-az/2016/daz-4-2016/autismus-durch-antidepressiva; https://www.zentrum-der-gesundheit.de/krankheiten/weitere-erkrankungen/autismus-uebersicht/autismus-antidepressiva
10 https://www.theguardian.com/tv-and-radio/2017/mar/20/sesame-street-autism-muppet-julia; https://www.pbs.org/newshour/arts/sesame-street-debuts-julia-first-character-autism; https://time.com/4082185/sesame-street-first-autistic-character/
11 https://translate.google.com/website?sl=en&tl=de&hl=en&u=https://www.health.harvard.edu/blog/what-is-neurodiversity-202111232645; https://www.amazon.de/Neurodiversit%C3%A4t-Autismus-P%C3%A4dagogik-Autismus-Spektrum-Band/dp/3170412663/ref=sr_1_20?__mk_de_DE=%C3%85M%C3%85%C5%BD%C3%95%C3%91&crid=2NBD5CLDGW06N&keywords=Autismus&qid=1680189748&s=books&sprefix=autismus%2Cstripbooks%2C120&sr=1-20
12 https://www.semanticscholar.org/paper/Premature-mortality-in-autism-spectrum-disorder-Hirvikoski-Mittendorfer-Rutz/d4cae0b1efaaaf1e6d4ad452636ea6a898bb7e67?p2df; https://jamanetwork.com/journals/jamapediatrics/fullarticle/2479467
13 Zit. nach The Defender, 14.3.2023, https://childrenshealthdefense.org/defender/herzzerreissend-pharma-sieht-exponentielles-wachstum-im-milliardenschweren-markt-fuer-autismus-medikamente/?lang=de
Autismus, Autimus-Spektrum-Störung, ASD, Antipsychotika, Breakthrough Therapy, Impfung, Neurodiversität